Table 3 Secondary outcomes
From: Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study
Hour −2 | Hour −1 | Hour 0 | Hour 1 | Hour 2 | Hour 3 | Hour 4 | Hour 5 | Hour 6 | Hour 7 | Hour 8 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Urine output, cc | |||||||||||
ATII | 41.7 (51.7) | 28.6 (32.4) | 45.9 (96.5) | 31.1 (58.0) | 33.7 (67.1) | 42.6 (59.8) | 35.9 (50.0) | 34.4 (57.2) | 36.1 (38.3) | 27.2 (33.3) | 23.8 (27.3) |
Placebo | 29.5 (69.8) | 12.4 (23.2) | 23.5 (41.8) | 17.5 (25.7) | 17.0 (32.0) | 16.3 (24.6) | 17.0 (34.7) | 16.8 (30.4) | 14.8 (26.3) | 18.0 (27.3) | 23.0 (34.4) |
Cardiac output, L/min | |||||||||||
ATII | 7.0 (2.7) | 6.0 (3.1) | 6.6 (2.6) | 6.3 (2.5) | 6.2 (2.5) | 5.9 (2.7) | 6.5 (2.4) | 6.1 (2.6) | 6.7 (3.3) | 6.3 (2.9) | 7.5 (3.1) |
Placebo | 6.3 (1.2) | 6.9 (2.5) | 6.5 (1.7) | 6.9 (1.8) | 6.4 (1.7) | 6.8 (3.0) | 7.3 (2.2) | 6.8 (1.5) | 7.3 (1.8) | 6.9 (2.5) | 7.0 (2.3) |
Central venous pressure | |||||||||||
ATII | 12.7 (5.5) | 12.9 (7.0) | 14.1 (8.9) | 14.8 (7.3) | 14.6 (7.4) | 14.8 (8.8) | 11.7 (3.9) | 12.1 (4.8) | 10.0 (2.9) | 12.6 (4.8) | 11.8 (3.8) |
Placebo | 16.0 (3.0) | 9.7 (2.1) | 12.6 (7.8) | 15.7 (9.3) | 17.3 (9.0) | 15.7 (7.3) | 16.4 (8.6) | 16.3 (6.7) | 14.2 (6.5) | 14.4 (7.1) | 13.2 (5.6) |
Mean arterial pressure | |||||||||||
ATII | 71.2 (13.6) | 72.3 (11.2) | 68.8 (7.0) | 74.8 (8.4) | 69.8 (8.6) | 73.1 (12.5) | 75.3 (14.2) | 68.9 (8.1) | 73.0 (10.5) | 72.3 (11.9) | 73.6 (11.5) |
Placebo | 71.2 (9.2) | 71.8 (6.5) | 73.0 (12.6) | 72.8 (9.5) | 67.8 (6.6) | 70.1 (6.4) | 71.3 (7.8) | 73.0 (4.7) | 75.9 (9.4) | 74.0 (10.6) | 74.5 (13.2) |
Lactate | |||||||||||
ATII | NA | NA | 4.6 (3.1) | NA | NA | NA | NA | NA | 5.2 (4.1) | NA | NA |
Placebo | NA | NA | 7.1 (5.2) | NA | NA | NA | NA | NA | 5.7 (3.9) | NA | NA |